ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Research Article

Monitoring disease activity and severity in lupus

[version 1; peer review: 2 approved with reservations]
PUBLISHED 10 Feb 2017
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the Lupus nephritis and neuropsychiatric lupus collection.

Abstract

Background: Systemic lupus erythematosus (SLE) is a relatively uncommon disease of young females in Pakistan. Usually, it has a relapsing-remitting course with variable severity and disease activity. Amongst the different clinical and laboratory parameters used to monitor disease activity in lupus, mean platelet volume (MPV) is a novel biomarker. Although MPV has been studied in other rheumatological conditions like rheumatoid arthritis, its role in adult SLE needs to be defined, especially in Pakistan. Methods: The aim of this study was to evaluate the role of MPV as a biomarker of disease activity in SLE. This study included 25 patients with active SLE, and another 25 participants with stable, inactive lupus. MPV was measured in each group and compared using SPSS version 16. MPV was also correlated with SLE disease activity index (SLEDAI) and erythrocyte sedimentation rate (ESR). Independent sample t-test and Pearson’s correlation tests were applied. Sensitivity and specificity of MPV were checked through ROC analysis. Results: The MPV of patients with active SLE (n=25, mean [M]=7.12, SD=1.01) was numerically lower than those in the inactive-SLE group (n=25, M= 10.12, SD=0.97), and this was statistically significant (P<0.001). MPV had an inverse relationship with both ESR (r=-0.93, P<0.001) and SLEDAI (r= -0.94, P<0.001). However, there was a strong positive correlation between ESR and SLEDAI (r=0.95, P<0.001). For MPV, a cutoff value of less than 8.5fl had a sensitivity of 92% and a specificity of 100% (P< 0.001). Conclusions: Higher disease activity in SLE is associated with a correspondingly low MPV.

Keywords

systemic lupus erythematosus, blood platelets, platelets aggregation

Abbreviations

MPV: Mean Platelet Volume, SLEDAI: Systemic Lupus Erythematosus Disease Activity Index, SLE: Systemic Lupus Erythematosus, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive Protein, ACR: American College of Rheumatology.

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that can affect any organ system of the body. It has an annual incidence of 5 per 100,000 of the general population1. There are racial and ethnic variations, with higher rates reported in Black and Hispanic peoples2. Usually, this disease with protean manifestations has a remitting relapsing course; however, it has a tendency to vary from acutely progressive to chronic indolent forms1,2.

The clinical manifestations of SLE range from constitutional symptoms, such as fever, sweats, weight loss, joint pains and skin rashes (including the classic butter fly rash), to more serious features, including the involvement of the central nervous system and kidneys. However, to make a clinical diagnosis of SLE, simultaneous or sequential presence of 4 out of a total of 11 criteria, proposed by the American College of Rheumatology (ACR), must be present3,4.

Considering the remitting relapsing nature of most cases of SLE, it is important to have a biomarker to monitor its disease activity. Although, the most effective and reliable tool to measure SLE disease activity is still open to debate, there are fortunately many validated measures, including the Systemic Lupus Activity Measure, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Lupus Activity Index, European Consensus Lupus Activity Measurement, and British Isles Lupus Activity Group5. These tools have been found to be beneficial in day to day practice6,7.

Notable issues, apart from some other technical limitations, with the aforementioned severity assessment indices are that these validated instruments are confusing, lengthy and time consuming. However, very recently, mean platelet volume (MPV) has been shown to be a very good and easily accessible marker of disease activity in lupus810. Although MPV has been studied well as a simple but reliable inflammatory biomarker in several diseases, such as rheumatoid arthritis, scleroderma, rheumatic fever, ankylosing spondylitis and even chronic obstructive pulmonary disease, there is still a relative scarcity of its role as a disease severity indicator in lupus1115. Therefore, we performed the present study to find out whether MPV does or does not correlate with SLEDAI and whether it can be used a predictor of lupus severity and activity.

Methods

Patient characteristics

This cross-sectional study was conducted in the Department of Medicine of Khyber Teaching Hospital (KTH; Peshawar, Pakistan) between January 2015 and July 2016. Medical records, intranet of our hospital and referrals by the general practitioners were the sources of recruitment. Patient information sheet, letters and direct contact by the investigators, who were directly involved in the provision of healthcare to potential subjects, were the chief methods of recruitment. This study was approved by the Ethics Review Committee of the hospital and a written informed consent was obtained from every participant (approval number, KTH/2015/Med-A/86C). The patient sample was collected using a consecutive-random sampling technique. Nevertheless, as is true of cross-sectional studies, confounding and sample selection bias may be limitations to the generalization of our results.

Patients from both genders in the age range of 18–70 years, and those with both either newly diagnosed or pre-existing SLE were included in the study. In order to avoid bias, only those patients with a normal platelet count were included. This is because; MPV is influenced by the number of platelets in circulation. The ACR criteria for the diagnosis of SLE was used as a diagnostic tool.

Individuals who had history of smoking, acute or chronic infectious diseases, hemoglobin >16.5 g/dl, thrombocytopenia (platelets <150,000/mm3), hypertension, angina pectoris, myocardial infarction, diabetes mellitus, hypo- or hyperthyroidism, anti-phospholipid syndrome, recurrent miscarriage, amyloidosis, thrombosis and acute or chronic renal failure were excluded from the study. Patients who had either clinical, biochemical or serological evidence of an autoimmune disorder other than SLE, such as rheumatoid arthritis, Sjogren’s syndrome or scleroderma, were also excluded from the study.

The sample size was calculated by using 5% margin of error and 95% CI on the WHO’s formula for determination of sample size in health studies (http://www.who.int/chp/steps/resources/sampling/en/). A total of 64 patients were assessed initially. However, only 50 of them satisfied the inclusion and exclusion criteria. The 50 participants recruited were divide into two equal groups, 25 subjects each in the active-SLE and the inactive-SLE groups, as detailed below.

SLEDAI

The participants were divided into two groups, active and inactive SLE groups. The division of the patients into two groups was based on their final score from using the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2000)16. Those who scored 5 or higher were classified as active-SLE, while those with a final score of less than 5 were regarded as patients with inactive-SLE. Patients with active-SLE, fulfilling the inclusion criteria (SLEDAI-2000), were admitted to any one of the five medical wards of KTH for further workup and treatment. However, those with stable inactive disease were recruited in the study from the Outpatient Department of KTH.

Measurement of MPV

A total of 5ml of venous blood was taken in an EDTA tube from every participant for the measurement of complete blood count, including hemoglobin, white blood cells, platelets, MPV, and erythrocyte sedimentation rate (ESR). All the blood samples were analyzed within less than one hour after sampling. The complete blood count, including all the hematological parameters, was performed using the same hematology analyzer, Medonic. The tests were performed and read by the same laboratory technician of KTH.

Data analysis

All the data was entered on a structured questionnaire specifically designed for this study (Supplementary File 1). Data was transferred to and analyzed using SPSS version 16. Means and standard deviations were determined for quantitative variables. Independent sample t-test was run to compare means of MPV between the two groups. ROC analysis was performed to estimate cutoff values for sensitivity and specificity of MPV. Finally, Pearson’s correlation test was used to assess any association between MPV, ESR and SLEDAI. P value of less than 0.05 was considered as significant.

Results

Of the 50 participants, 84% were female and 16% were male. There were 4 males and 21 females in each of the active- and inactive-SLE groups, respectively. Other demographic details are shown below (Figure 1). The overall mean age of all the participants was 27.94±2.52 years. The mean age of the patients in the active-SLE group (M=27.84, SD=2.06) was comparable to the inactive-SLE group (M=29.60, SD= 2.38). The clinical features of patients with active- and inactive-SLE are shown in Table 1 and Table 2, respectively. In the active-SLE group, 11 (44%) patients had evidence of clinically significant proteinuria; details of the histological sub-type of lupus nephritis are given in Table 3.

468f67b9-2bc7-49fb-a41e-95709f5b06a1_figure1.gif

Figure 1. Demographic details of patients in each group (n=25).

Table 1. Overview of clinical characteristics of patients with active-SLE.

CLINICAL FEATURESPATIENTS,
N (%)
Polyarthritis22 (88)
Butterfly rash16 (64)
Photosensitivity20 (80)
Patchy alopecia15 (60)
Pleurisy14 (56)
Pericarditis2 (8)
Neuropsychiatric problems13 (52)
Oral ulcers20 (80)
Proteinuria (>0.5gm/day)11 (44)
Anti-dsDNA antibodies24 (96)
Antinuclear factor23 (92)

Table 2. Overview of the clinical characteristics of patients with inactive-SLE.

CLINICAL FEATURESPATIENTS,
N (%)
Non-specific aches and pains17 (67)
Malaise14 (54)
Dyspepsia13 (53)
Anorexia10 (40)
Photosensitivity6 (23)
Non-scarring alopecia5 (19)

Table 3. Overview of the renal histology in 11 patients with active-SLE and proteinuira.

Histological type of lupus nephritisPatients,
N (%)
Focal proliferative glomerulonephritis3 (27)
Diffuse proliferative glomerulonephritis7 (64)
Membranous glomerulonephritis1 (9)

The MPV of patients with active-SLE (n=25, M=7.12, SD=1.01) was numerically lower than those in the inactive-SLE group (n=25, M= 10.12, SD=0.97). An independent sample t-test was run to compare the means of the two groups. The assumption of normality was tested by Kolmogorov-Samirnov test and was found tenable (P> 0.05).Moreover, similar results were obtained on Skewness and Kurosis testing (skewness=0.01, kurtosis= -1.06). The assumption of homogeneity of variances was tested using Levene’s test and was found tenable (F (48) = 0.23;P= 0.63). The results of the independent t-test showed a statistically significant difference between the mean values of MPV of the two groups(t (48) = 10.69;P<0.001; Cohen’s D= 3.02). The 95% Confidence Interval (CI) was -3.56 to -2.44. Receiver operator characteristic (ROC) curve was used to check the specificity and sensitivity of MPV (Figure 2). The ROC curve had an area under the curve of 0.98. At a value of 8.5fl for MPV, the sensitivity and specificity were 92% and 100%, respectively, (P<0.001;95%CI -0.96 to +1.01). At a cutoff value of 8.5fl, MPV has a maximum sensitivity and specificity. Therefore, we recommend that, at an MPV value of <8.5fl, the probability of SLE increases remarkably.

468f67b9-2bc7-49fb-a41e-95709f5b06a1_figure2.gif

Figure 2. ROC analysis for sensitivity and specificity of mean platelet volume.

The SLEDAI scores between the two groups, active-SLE (M=16.36, SD=4.48) and inactive-SLE (M=3, SD=0.82), varied at a statistically significant level of P<0.001. The ESR was higher in patients with active SLE (M=49.52, SD=12.93) than those with stable disease (M=13.76 SD=1.72)(P<0.001). The details of the different hematological parameters are given in Table 4.

Table 4. Comparison of different test variables between the two study groups.

SLEDAI, Systemic Lupus Erythematosus Disease Activity; MPV, mean platelet volume; ESR, erythrocyte sedimentation rate; WBC, white blood cells; Hb, hemoglobin.

VariableActive-SLEInactive-SLE P value
MeanSDMeanSD
SLEDAI16.364.483.000.82< 0.001
MPV (fl) 7.121.0110.120.97< 0.001
ESR (1st hour)49.5212.9313.761.72< 0.001
Platelets×103/mm3259.721.10259.681.030.89
WBC/mm35422.00396.685896.0079.53< 0.001
Hb (gm/dl)11.641.0413.560.87< 0.001

Pearson’s correlation test was run to assess any relationship between MPV, SLEDAI and ESR in the active-SLE group. The results showed a statistically significant, negative correlation of MPV with both ESR (r= -0.93, P<0.001) and SLEDAI, (r= -.94, P<0.001).Moreover, there was a strong positive correlation between ESR and SLEDAI (r=0.95, P<0.001). Hence, it can be argued that increased disease activity of SLE is associated with both a higher ESR and SLEDAI score, and a correspondingly low MPV (P<0.001).

GroupSLEDAIMPVESRWBCHBPlateletsAgeGender
221114600014260302
231015600013260312
24917590013259322
221114590014260332
231014600013259341
24916600013259291
221113590014260282
231014580013260272
24915588813258262
221113581414259262
231013589913260262
24914578913259272
221214580014261282
231015579013261282
24916576012259292
221111600015263292
231014590014260302
24915587913260292
221210590015259302
231112590014260312
24915600012259331
221111600015259332
231014590014260322
24914580013260311
231011588815258282
18930581414259272
19930589913260292
110832578913259262
111833580013261272
112836579012261262
113838576012258272
113837600012259262
113836590012260262
113840587912259252
114843590013261262
115747550012261252
116747545612259251
117750541112263252
118755530011260261
119759529811260252
120760521311259252
121662510011260252
122663508911259252
121663501011259262
120661500011260272
120660498911260282
119659496911258292
121664494010259261
122666487910260271
Dataset 1.Raw data of disease severity indicators in lupus.
This file contains data regarding disease severity indicators and demographics of patients with SLE. This coded data was stored on SPSS version 16. Group: 1, active-SLE; 2, inactive-SLE. Gender: 1, male; 2, female. SLEDAI, systemic lupus erythematosus disease activity index; MPV, mean platelet volume; ESR, erythrocyte sedimentation rate; WBC, white blood cell (thousand/mm3); Hb, hemoglobin (gm/dl); platelets, platelet count × 103.

Discussion

SLE, which is more common in Black women, has a female to male ratio of approximately 9:111. Our study group comprised of 84% female and 16% male population. Furthermore, most of the participants in our study were in the third decade of life. Participants with active-SLE were younger than those with the stable form of the disease. These findings are comparable to international statistics17,18. We observed that MPV was significantly lower in patients with active lupus than those without a flare. Similarly, we found that, MPV had a tendency to be lower with a correspondingly higher ESR in individuals with actively flaring SLE and vice versa. Moreover, we observed that SLEDAI was as effective as both ESR and MPV, as an indicator of disease activity in patients with SLE.

Gasparyan et al. concluded that high MPV correlated with a variety of diseases, like cardio- and cerebrovascular disorders, venous and arterial thrombosis and low-grade inflammatory conditions19. However, it was observed that, high intensity inflammatory disorders, such as active rheumatoid arthritis or relapses of familial Mediterranean fever, had low values of MPV, which could be reverted with anti-inflammatory medications20,22. Although we did not check the effect of anti-inflammatory medications, like corticosteroids, on MPV, we observed a strong inverse relationship of MPV with lupus severity and activity. Therefore, we recommend MPV as a global marker of disease activity in patients with SLE.

Apart from MPV, ESR has traditionally been used as a marker of disease severity in patients with inflammatory conditions, and SLE, specifically23. Similarly, C-reactive protein (CRP) has been studied, but not been found to be a marker of disease activity in lupus24. It is worth mentioning that, usually, there is a discordance between ESR and CRP in actively diseased SLE patients25. In our study, ESR correlated positively with both MPV and SLEDAI, which is consistent with these previous results.

Why is MPV low in active SLE? The answer cannot be clearly stated. However, previous studies have shown that, in active inflammatory conditions, especially rheumatoid arthritis and SLE, large and activated platelets are consumed preferentially at the site of inflammation, leaving small platelets behind2021. This may also explain lower MPV values in actively flaring SLE patients in our study group.

Considering active-SLE as a state of severe inflammation, those with active disease in our study were treated with 1g daily dose of methylprednisolone for three days, followed by a maintenance dose of 1mg/Kg oral prednisolone for another 4–6 weeks. Although, all participants with active lupus achieved dramatic symptomatic and clinically obvious improvement, MPV was not studied after the completion of steroid therapy. However, in other studies, where pre-treatment MPV was compared with post-treatment MPV, it was observed that, after successful treatment with anti-inflammatory medications, MPV reverted back to normal2126. Considering this data, we would advocate future studies focusing on comparing pre- and post-treatment MPV in patients treated with corticosteroids for acute flare of SLE.

It is noteworthy that; although, most of the studies found an inverse relationship between active-SLE and MPV in adults, a positive association was observed between MPV and disease activity in juvenile lupus erythematosus10. This finding of positive correlation between MPV and disease activity in juvenile lupus is in sharp contrast to the results of our and similar previous studies8,9.

Notably, the results of this study were in accordance with the expectations of authors. Moreover, considering recent research studies showing a link between low MPV and disease activity in SLE patients, our study will add further evidence. However a limitation to the conduct and results of this study was a small sample size. This is because, SLE is not very common in Pakistan. Therefore, in order to highlight the actual role of MPV as a biomarker of lupus severity, we recommend that, cohort studies should be done in future, both in Pakistan and abroad.

Conclusions

MPV is an excellent biomarker to monitor disease activity in SLE, as higher disease activity will reduce MPV and vice versa. Moreover, MPV has an inverse relationship with both ESR and SLEDAI. At a cutoff value of less than 8.5fl, MPV has an excellent sensitivity and specificity.

Ethics approval and consent

This study was approved by Ethics Review Committee of Khyber Teaching Hospital, Peshawar, Pakistan (approval number, KTH/2015/Med-A/86C). Informed written consent was obtained from every participant.

Data availability

Dataset 1: Raw data of disease severity indicators in lupus. This file contains data regarding disease severity indicators and demographics of patients with SLE. This coded data was stored on SPSS version 16. Group: 1, active-SLE; 2, inactive-SLE. Gender: 1, male; 2, female. SLEDAI, systemic lupus erythematosus disease activity index; MPV, mean platelet volume; ESR, erythrocyte sedimentation rate; WBC, white blood cell (thousand/mm3); Hb, hemoglobin (gm/dl); platelets, platelet count × 103. doi, 10.5256/f1000research.10763.d15106427

Comments on this article Comments (0)

Version 3
VERSION 3 PUBLISHED 10 Feb 2017
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Khan A, Haider I, Ayub M and Khan S. Monitoring disease activity and severity in lupus [version 1; peer review: 2 approved with reservations]. F1000Research 2017, 6:126 (https://doi.org/10.12688/f1000research.10763.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 10 Feb 2017
Views
21
Cite
Reviewer Report 17 Feb 2017
Alina Dima, Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark 
Approved with Reservations
VIEWS 21
  1. Title: I don’t find the term “monitoring” appropriate as it is presented a cross-sectional study with only one MPV determination and I so think that the use of assessment or determination could be tried.
    Also
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Dima A. Reviewer Report For: Monitoring disease activity and severity in lupus [version 1; peer review: 2 approved with reservations]. F1000Research 2017, 6:126 (https://doi.org/10.5256/f1000research.11605.r20320)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 24 Feb 2017
    Abidullah Khan, Department of Medicine, Khyber Teaching Hospital, Peshawar, 25000, Pakistan
    24 Feb 2017
    Author Response
    We are really grateful to Alina Dima for her invaluable comments on our article. Please find below a point-wise response to the comments.
    1. Title: "I don’t find the
    ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 24 Feb 2017
    Abidullah Khan, Department of Medicine, Khyber Teaching Hospital, Peshawar, 25000, Pakistan
    24 Feb 2017
    Author Response
    We are really grateful to Alina Dima for her invaluable comments on our article. Please find below a point-wise response to the comments.
    1. Title: "I don’t find the
    ... Continue reading
Views
23
Cite
Reviewer Report 13 Feb 2017
Guillermo Delgado-García, National Institute of Neurology and Neurosurgery, Mexico City, Mexico 
Approved with Reservations
VIEWS 23
In this study, Khan et al explored the relationship between SLE disease activity and mean platelet volume (MPV). After reading this article, I have the following suggestions:
  1. I think it would be good if the title
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Delgado-García G. Reviewer Report For: Monitoring disease activity and severity in lupus [version 1; peer review: 2 approved with reservations]. F1000Research 2017, 6:126 (https://doi.org/10.5256/f1000research.11605.r20146)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 24 Feb 2017
    Abidullah Khan, Department of Medicine, Khyber Teaching Hospital, Peshawar, 25000, Pakistan
    24 Feb 2017
    Author Response
    We thank Guillermo Delgado-Garcia from Mexico for reading our manuscript thoroughly and for pin-pointing various discrepancies. We have now corrected the shortcomings and we believe that, the changes made in ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 24 Feb 2017
    Abidullah Khan, Department of Medicine, Khyber Teaching Hospital, Peshawar, 25000, Pakistan
    24 Feb 2017
    Author Response
    We thank Guillermo Delgado-Garcia from Mexico for reading our manuscript thoroughly and for pin-pointing various discrepancies. We have now corrected the shortcomings and we believe that, the changes made in ... Continue reading

Comments on this article Comments (0)

Version 3
VERSION 3 PUBLISHED 10 Feb 2017
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.